妇科良、恶性肿瘤患者CD_3AK细胞和LAK细胞体外扩增能力比较

Comparative study on the proliferative ability of CD_3AK cells and LAK cells of patients with benign and malignant gynecological tumors in vitro

为探讨妇科良、恶性肿瘤患者CD3AK细胞的体外增殖能力，对其外周血淋巴细胞用CD3MAb＋IL－2诱导CD3AK细胞，体外动态观察CD3AK细胞增殖倍数，并与同期培养的LAK细胞进行对比。结果：①良性肿瘤组CD3AK细胞在培养第1周，增殖倍数高于恶性肿瘤组，但无显著性差异（P＞0．05），第2、3、4周，良、恶性肿瘤组CD3AK的增殖倍数较接近；②LAK细胞增殖倍数，在良性肿瘤组培养第1周时显著高于恶性肿瘤组（P＜0．05），培养第2、3周也高于恶性肿瘤组，但无统计学意义（P＞0．05）。结果提示：CD3AK细胞和LAK细胞短期培养时，不宜取材于恶性肿瘤患者。

The PBMCs(peripheral blood mononuclear cells) of patients with benign and malignant gynecological tumor were induced into CD3AK cells with anti-CD3 monoclonal antibody(CD3MAb) plus interleukin-2(IL-2). The proliferative multiple of CD3AK cells was analysed continuously. LAK cells were cultured and compared with the CD3AK cells cultured at the same time. The results showed that: ① the proliferative multiple of CD3AK cells in the benign gynecological tumor group was higher than that in the malignant gynecological tumor group at the 1st week of culture, but there was no significant difference (P >0.05), and was similar in the benign and malignant tumor at the 2nd, 3rd and 4th week of cultures; ②the proliferative multiple of LAK cells in benign gynecological tumor was significantly higher than that in malgnant gynecological tumor at the 1st week (P < 0. 05). It is suggested that if CD3AK cells and LAK cells were cultured in short-term (< 7 days), they had better be taken from the patients with bengin,not malignant tumors.